Breaking AI & Tech News Analyzed

The latest offering from writer Theo Jamieson and director Adam Lenson is a boldly conceived musical that thrusts a turbulent romance into a sci‑fi framework. The story follows a young astronaut, Daniel, who vanishes from his shuttle with barely enough fuel, prompting a quest to uncover the motives behind his reckless flight.Stuart Thompson (as Daniel) and Poppy Gilbert (as Emily) anchor the piece with performances that are both visceral and nuanced. Their chemistry captures the push‑pull of a relationship scarred by childhood bullying, parental betrayal, and a shared history of trauma, delivering songs that soar and hit hard.Visually, the production leans heavily on interstellar projections that transform the stage into a shifting cosmos, while the score oscillates between Sondheim‑style wit and full‑blown symphonic passages. This combination creates an epic sense of strangeness that distinguishes Flyby from more conventional West End fare.However, the narrative’s fragmented structure hampers its emotional payoff. The non‑chronological storytelling leaves critical gaps, and the metaphor of being "stranded in space" feels over‑extended—especially with the protagonist’s surname, Defoe, a thin nod to Robinson Crusoe. The three narrators, played by Simbi Akande, Gina Beck, and Rupert Young, often drift into digressive asides that dilute the central arc.Despite these flaws, moments of brilliance emerge, particularly in the musical’s treatment of mental‑health themes. The show hints at the potential to join the ranks of modern theatre successes like Next to Normal and Dear Evan Hansen, should its structural rough edges be smoothed.The production is currently staged at Southwark Playhouse, Borough, London and will run through 16 May. Audiences seeking a daring blend of emotional intensity and cosmic spectacle will find Flyby a compelling, if imperfect, experience.

Prosecutors in Florida have moved to subpoena Tiger Woods' prescription drug records from a pharmacy, following his recent vehicle crash and DUI arrest. The legendary golfer's records from Lewis Pharmacy in Palm Beach, Florida, are being sought for the period from the start of the year through last month.The subpoena aims to obtain comprehensive details on Woods' prescription medication, including:the times prescriptions were filledthe number of pills dispenseddosage amountsany instructions provided with the medication, such as warnings about drivingAccording to court documents, prosecutors in Martin County, Florida, are seeking this information to aid in their investigation. Any objections to the subpoena must be filed within 10 days. Woods has pleaded not guilty in his DUI case.Woods' vehicle crashed on a beachside road on Jupiter Island, where he was traveling at high speeds in a 30-mile per hour zone. The accident resulted in $5,000 in damage to the truck. Although a Breathalyzer test showed no signs of alcohol, Woods refused a urine test.Following the incident, Woods announced he would be stepping away to seek treatment. This is not his first leave of absence following a car crash; in 2009, he took a four-month break after a previous accident.

A 47‑year‑old woman who had endured three life‑threatening autoimmune diseases for more than a decade is now living a near‑normal life after an experimental CAR‑T cell therapy reset her immune system at University Hospital Erlangen in Germany.Before the procedure she had exhausted nine different treatments with no lasting benefit, relying on daily blood transfusions and continuous anticoagulation to manage her illnesses.Within weeks of the infusion, doctors observed rapid improvement in all three conditions—a world‑first outcome. She has remained in treatment‑free remission for 14 months and has largely returned to everyday activities.Prof Fabian Müller, who led the team, called the speed and depth of the response “remarkable” and said the therapy “significantly improved her quality of life.” He emphasized that clinical trials are required to determine how durable the effect is and whether it can help other autoimmune patients.The patient suffered from three distinct disorders: autoimmune haemolytic anaemia (AIHA), where rogue immune cells destroy red blood cells; immune thrombocytopenia (ITP), which depletes platelets and raises bleeding risk; and antiphospholipid syndrome (APS), which promotes dangerous blood clots. All three stem from malfunctioning B‑cells.With no conventional options left, doctors turned to CAR‑T therapy, a technique that has revolutionised treatment for certain cancers. They harvested her white‑blood cells, isolated the T‑cells, engineered them to recognise the CD19 protein on B‑cells, and reinfused the modified cells.The engineered T‑cells swiftly eliminated the pathogenic B‑cells. She received her last blood transfusion a week after treatment and was able to perform routine tasks within two weeks. Follow‑up tests showed a reconstituted, healthy B‑cell population, suggesting an immune reset. The findings were published in the journal Med.She still exhibits a mildly low white‑cell count and slightly elevated liver enzymes, which researchers attribute to the cumulative impact of prior therapies rather than the CAR‑T product.Rheumatology expert Prof Ben Parker of Manchester University NHS Foundation Trust described the case as encouraging, noting that “the prolonged response off normal therapy suggests there has been an immune reset.” However, he warned that case reports alone cannot confirm efficacy and highlighted ongoing trials for lupus, myositis, multiple sclerosis, systemic sclerosis, vasculitis, and other autoimmune conditions.

As rising temperatures push snakes and humans into closer contact, the world faces an estimated 5.5 million snakebites each year, resulting in 138,000 deaths and 400,000 lasting disabilities. In response, a Wisconsin‑based amateur scientist has taken an extreme route to help solve the crisis.For almost 20 years, Tim Friede, a former window cleaner, allowed some of the planet’s most lethal snakes to bite him, accumulating over 200 intentional bites. His goal: to provoke his own immune system into producing antibodies that could be harvested for a near‑universal antivenom.The endeavor has been perilous. Friede survived a coma after being bitten by two cobras within an hour, endured anaphylactic shocks, lost tissue in a finger, and even had to cut necrotic muscle from his leg. Yet he persisted, eventually becoming immune to the inland taipan—the world’s most venomous snake, whose single bite can kill more than 100 people.In 2019, California biotech firm Centivax hired Friede to extract his antibodies. Early laboratory work showed that his serum can neutralise toxins from 19 elapid species, including cobras, mambas, taipans, coral snakes and kraits—roughly half of all venomous snakes worldwide.The next step is a veterinary trial in Australia, slated for later this year, before any human application. If successful, the antivenom could dramatically reduce the burden of snakebite in low‑income regions across Asia and Africa, where most victims live.Climate scientists warn that warming climates will expand snake habitats and increase human exposure, as illustrated by the recent surge of rattlesnake bites in California’s Ventura County. This amplifies the urgency for scalable, affordable antivenoms, especially as international aid budgets face cuts and manufacturing capacity remains insufficient.Friede’s unconventional path underscores a broader lesson: confronting emerging health threats may require bold, unconventional science, but the potential payoff—a life‑saving treatment for millions—could be transformative.

The United States' newly disclosed arrangement to transfer certain detainees to third‑country destinations has triggered a wave of criticism across the Democratic Republic of Congo (DRC). Local authorities and human‑rights groups argue that the deal undermines the DRC's sovereignty and raises serious concerns about the treatment of deportees. While details of the agreement remain limited, the backlash underscores growing tensions over migration policies that involve multiple nations. Critics in the DRC are calling for greater transparency and for the United States to reassess the humanitarian implications of the deportation scheme. Stakeholders emphasize that any such arrangement must comply with international law and respect the rights of individuals facing removal, warning that failure to do so could damage diplomatic relations between the two countries.

Researchers have made a significant breakthrough in understanding why weight-loss medications, such as GLP1 receptor agonists, work better for some individuals than others. A recent study published in Nature has identified genetic variations in two genes involved in gut hormone pathways that regulate appetite and digestion. These genetic variations may help account for different weight-loss results or side-effects when taking glucagon-like peptide 1 (GLP1) medicines, which mimic natural gut hormones to regulate appetite, insulin release, and digestion. The study analyzed data from 27,885 patients on GLP1 drugs and found that specific genetic variants were associated with slightly more weight loss or side-effects like nausea and vomiting. The findings suggest that genetic differences may contribute to why people respond differently to weight-loss jabs. However, the overall impact of genetics appeared to be modest, with non-genetic factors such as sex, drug type, dose, and duration appearing to explain a substantially larger proportion of variability. The study's results reinforce that while there is substantial variability in response to GLP1 therapies, genetics is only one part of a much more complex picture. According to Marie Spreckley, an obesity expert at the University of Cambridge, the study provides plausible evidence that genetic variants could affect outcomes. However, she notes that the magnitude of these genetic effects is small in clinical terms, and that behavioral, clinical, and treatment-related factors remain the dominant drivers of outcomes. The study's authors suggest that their findings could support future efforts to use genetic information when making treatment choices for obesity. However, Spreckley cautions that the evidence is not yet sufficient to support using genetic information to guide treatment decisions in routine clinical practice.

Health‑service workers have voiced strong unease after it emerged that engineers from the controversial US tech firm Palantir were issued NHS.net email accounts. Those accounts unlock a directory containing contact details for as many as 1.5 million NHS staff members, as well as access to SharePoint file‑sharing and Microsoft Teams groups used by the service. Palantir’s engineers are supporting the rollout of the Federated Data Platform (FDP), a £300 million contract awarded in 2023 to link patient records across disparate NHS systems. The government touts FDP as a cornerstone of its plan to "reinvent the NHS" by moving from analogue to digital, promising faster diagnoses, better appointment allocation and more personalised treatment. While the use of NHS email accounts by external suppliers is not unprecedented, Palantir’s reputation for AI‑driven surveillance and military‑grade technology has amplified staff, patient and human‑rights concerns. Rory Gibson, a resident doctor, warned that his personal contact details should not be accessible to a company that also works on drone‑strike systems. The Guardian has identified at least six Palantir engineers who have been given NHS.net credentials. In response, a Palantir spokesperson argued that such access is "normal practice for government suppliers" and cited official guidance that government systems are more secure than external alternatives. Palantir claims its software has already yielded measurable benefits: 110,000 additional operations, a 15.3% reduction in discharge delays and a 6.8% rise in cancer diagnoses within 28 days of referral. The company stresses that it merely provides software, with data usage remaining under NHS control and subject to strict contractual confidentiality. David Rowland, director of the Centre for Health and the Public Interest, acknowledged that granting NHS email addresses may not breach rules but highlighted the "deep ethical concerns" that Palantir’s profit‑driven model clashes with NHS values. He called for a comprehensive review of which private firms receive public‑sector funding. Some NHS staff reported being placed in virtual Teams meetings with Palantir personnel who joined using NHS credentials, without any disclosure of their employer – a practice that further eroded trust. Under the NHSmail access policy, "independent sector organisations" delivering health and social‑care services nationally may use NHSmail. An unrestricted NHS.net account can reveal staff roles, locations, workplace details and even grant access to commercial "Blue Light" discounts. Palantir’s technology is already deployed by UK police forces and the Ministry of Defence, prompting critics to warn that its "drag‑and‑drop" interoperability could facilitate state overreach, including a potential British analogue of the US Immigration and Customs Enforcement agency. The firm’s founders include US businessman and former Trump supporter Peter Thiel and CEO Alex Karp, both known for advocating aggressive surveillance tools. Its UK arm is led by Louis Mosley, grandson of historic British fascist leader Oswald Mosley. An NHS spokesperson reiterated that all suppliers, including Palantir, operate strictly under NHS instruction, with data access governed by robust contractual confidentiality obligations.

Mariam Sabbah, a 10-year-old Palestinian girl, lost her arm in an Israeli missile attack on Gaza and has arrived in the UK for specialist treatment. She was accompanied by her mother, Fatma Salman, and two brothers at Heathrow airport.The family was met with a warm welcome, including gifts, balloons, and bouquets. Mariam's arm was amputated after a missile tore through her family's home in Deir al-Balah. Her family had initially hoped to go to the US for treatment but was unable to due to visa restrictions.According to the World Health Organization (WHO), over 11,000 patients have been evacuated from Gaza, with an estimated 18,500 more in need of urgent care. The UK government had announced a medical evacuation scheme last year, which led to the arrival of Mariam and her family in the UK for privately funded specialized treatment.Aid organizations have called on the UK government to increase efforts to help evacuate critically ill and injured children from Gaza. The WHO announced on Monday that it would suspend medical evacuations after a contracted worker was killed.Mosab Nasser, co-founder of FAJR Global, stated that more lives would be lost due to the WHO's decision. The UK government scheme relies on the WHO to provide a list of patients identified as priority cases by medical specialists in Gaza.Campaigners have expressed concerns that without urgent action, more preventable illness and deaths will occur. Since October 2023, Egypt, the United Arab Emirates, and Qatar have assisted the most number of patients medically evacuated from Gaza.

The World Health Organization (WHO) has suspended medical evacuations from Gaza to Egypt after a contract worker was killed by Israeli fire. The incident occurred on Monday, and WHO Director General Tedros Adhanom Ghebreyesus expressed his devastation over the confirmation of the worker's death.The WHO did not elaborate on the incident but stated that it was under investigation by the relevant authorities. Two staff members who were present during the incident were not injured. The medical evacuation of patients from Gaza via Rafah to Egypt, which had been planned for Monday, was suspended, and further evacuations will remain suspended until further notice.The Rafah crossing, which is the only crossing in Gaza that does not link to Israel, was reopened in February after a long closure by the Israeli military. This crossing is crucial for the entry of humanitarian supplies and for those in need of medical aid to leave and seek treatment abroad. The WHO has been overseeing coordination between Egypt and Israel since the opening of the Rafah crossing to facilitate those evacuations.However, crossing numbers have been far below expectations due to intense checks during the process by the Israeli authorities. Israel has also continued to limit the entry of humanitarian aid into the besieged territory and shut the crossing in the early days of the United States-Israeli war on Iran. Israel has repeatedly violated the ceasefire that came into force on October 10 after two years of devastating war.Referring to the incident on Monday in which a driver of a WHO car was killed, Israel's mission in Geneva said troops identified an unmarked vehicle approaching them and posing an immediate threat and they fired warning shots in response. The vehicle continued to accelerate towards the troops, who then responded with additional fire, and a hit was identified. The incident is under review.